A novel high-affinity human monoclonal antibody to mesothelin

International Journal of Cancer

Volumn 128, Issue 9, 2011, Pages 2020-2030

  Ho, Mitchell ^a   Feng, Mingqian ^a   Fisher, Robert J ^b   Rader, Christoph ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CA125 MUC16; Human monoclonal antibody; Mesothelin; Mesothelioma; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BACTERIAL TOXIN; CA 125 ANTIGEN; EPITOPE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOTOXIN; MESOTHELIN ANTIBODY; MONOCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER CELL; CELL SURFACE; CONTROLLED STUDY; DRUG ISOLATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; MESOTHELIOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHAGE DISPLAY; PRIORITY JOURNAL; PSEUDOMONAS;

ADP RIBOSE TRANSFERASES; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BACTERIAL TOXINS; CELL LINE, TUMOR; CELL SEPARATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXOTOXINS; FLOW CYTOMETRY; GPI-LINKED PROTEINS; HUMANS; IMMUNOTHERAPY; MEMBRANE GLYCOPROTEINS; PEPTIDE LIBRARY; POLYMERASE CHAIN REACTION; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; VIRULENCE FACTORS;

EID: 79952479229     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25557     Document Type: Article

References (36)

1. Mabuchi S, Morishige K, Kimura T. Use of monoclonal antibodies in the treatment of ovarian cancer. Curr Opin Obstet Gynecol 2010;22:3-8.
2. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 1992;50:373-81.
3. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996;93:136-40. (Pubitemid 26041483)
4. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008;44:46-53. (Pubitemid 350262830)
5. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003;27:1418-28. (Pubitemid 37315193)
6. Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGerald D, Pastan I. Mesothelin expression in human lung cancer. Clin Cancer Res 2007;13:1571-5. (Pubitemid 46450449)
7. Hellstrom I, Raycraft J, Kanan S, Sardesai NY, Verch T, Yang Y, Hellstrom KE. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev 2006;15:1014-20. (Pubitemid 43823532)
8. Ho M, Onda M, Wang Q, Hassan R, Pastan I, Lively M. Mesothelin is shed from tumor cells. Cancer Epidemiol Biomarkers Prev 2006;15:1751.
9. Bast RC, Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331-7. (Pubitemid 12235035)
10. Yin BWT, Lloyd KO. Molecular cloning of the CA 125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001;276:27371-5.
11. O'Brien TJ, Beard JB, Underwood LJ, Shigemasa K. The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumour Biol 2002;23:154-69. (Pubitemid 44858307)
12. O'Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol 2001;22:348-66. (Pubitemid 34062947)
13. Bast RC, Klug TL, St. John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Knapp RC. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-7. (Pubitemid 13014028)
14. Bateman AC, al-Talib RK, Newman T, Williams JH, Herbert A. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression. Histopathology 1997;30:49-56.
15. Attanoos RL, Webb R, Dojcinov SD, Gibbs AR. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Histopathology 2002;40:237-44. (Pubitemid 34227114)
16. Blalock TD, Spurr-Michaud SJ, Tisdale AS, Heimer SR, Gilmore MS, Ramesh V, Gipson IK. Functions of MUC16 in corneal epithelial cells. Invest Ophthalmol Vis Sci 2007;48:4509-18. (Pubitemid 351260966)
17. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004;279:9190-8. (Pubitemid 38295982)
18. Scholler N, Garvik B, Hayden-Ledbetter M, Kline T, Urban N. Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery. Cancer Lett 2007;247:130-6. (Pubitemid 44959415)
19. Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, Bera TK, Connor J, Sathyanarayana BK, Lee B, Pastan I, Patankar MS. Mesothelin-CA125 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 2006;5:50-65.
20. Kaneko O, Gong L, Zhang J, Hansen JK, Hassan R, Lee B, Ho M. A binding domain on mesothelin for CA125/MUC16. J Biol Chem 2009;284:3739-49.
21. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer 2006;6:559-65. (Pubitemid 43980544)
22. Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, Chao Q, Jacob S, Turchin H, Gibbs L, Phillips MD, Mudali S, et al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun 2007;19:7:20.
23. Huls GA, Heijnen IA, Cuomo ME, Koningsberger JC, Wiegman L, Boel E, van der Vuurst de Vries AR, Loyson SA, Helfrich W, van Berge Henegouwen GP, van Meijer M, de Kruif J, et al. A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments. Nat Biotechnol 1999;17:276-81. (Pubitemid 29123037)
24. Ho M, Hassan R, Zhang J, Wang QC, Onda M, Bera T, Pastan I. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res 2005;11:3814-20. (Pubitemid 40685601)
25. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, McCafferty J, Hodits RA, Wilton J, Johnson KS. Human antibodies with subnanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 1996;14:309-14.
26. Ho M, Pastan I. In vitro antibody affinity maturation targeting germline hotspots. Methods Mol Biol 2009;525:293-308.
27. Rader C, Popkov M, Neves JA, Barbas CF III. Integrin alpha(v)beta3 targeted therapy for Kaposi's sarcoma with an in vitro evolved antibody. FASEB J 2002;16:2000-2.
28. Ho M, Kreitman RJ, Onda M, Pastan I. In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. J Biol Chem 2005;280:607-17.
29. Karlsson R, Katsamba PS, Nordin H, Pol E, Myszka DG. Analyzing a kinetic titration series using affinity biosensors. Anal Biochem 2006;349:136-47. (Pubitemid 43129567)
30. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. Sequences of proteins of immunological interest, 5th edn. Bethesda, MD: National Institutes of Health (National Institutes of Health Publication No. 91-3242), 1991.
31. Lefranc MP. IMGT, the international immunogene tics database. Nucleic Acids Res 2001;29:207-9.
32. Chowdhury PS, Viner JL, Beers R, Pastan I. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci USA 1998;95:669-74. (Pubitemid 28083801)
33. Chowdhury PS, Pastan I. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotechnol 1999;17:568-72. (Pubitemid 29262920)
34. Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, Hellström KE, Hellstróm I. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA 1999;96:11531-6. (Pubitemid 29487415)
35. Onda M, Willingham M, Nagata S, Bera TK, Beers R, Ho M, Hassan R, Kreitman RJ, Pastan I. New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, western blotting, and ELISA. Clin Cancer Res 2005;11:5840-6. (Pubitemid 41170311)
36. Feng Y, Xiao X, Zhu Z, Streaker E, Ho M, Pastan I, Dimitrov DS. A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity. Mol Cancer Ther 2009;8:1113-18.